UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 2023, 2026

	Vaxart, Inc.
	(Exact name of registrant as specified in its charter)

Delaware	001-35285	59-1212264
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)
170 Harbor Way, Suite 300, South San Francisco, California		94080
310 Utah Ave, Suite 150, South San Francisco, California		94080
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code:

(650) 550-3500

~~Not~~170 ~~Applicable~~Harbor Way, Suite 300, South San Francisco, California 94080 (Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading symbol		Name of each exchange on which registered
Common Stock, $0.0001 par value		VXRT		*

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

* The registrant’s common stock ~~trades~~is ~~exclusively~~quoted on the OTCQX® Best Market under the symbol “VXRT.”

Item 85.0102 ~~Other~~Departure ~~Events~~of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On April 2023, 2026, ~~Vaxart,~~following ~~Inc.~~a (recommendation by the ~~“Company”)~~Nominating ~~entered~~and ~~into~~Governance anCommittee ~~amendment~~of (the ~~“Amendment”)~~Board toof ~~its~~Directors ~~lease agreement~~ (the “~~Utah Avenue Lease~~Board”) ~~with~~of aVaxart, ~~landlord~~Inc. (the “~~Utah Avenue Landlord~~Company”), ~~relating to certain properties currently leased to~~ the ~~Company~~Board ~~that~~appointed ~~are~~James ~~located~~B. ~~on Utah Avenue in South San Francisco~~Breitmeyer, ~~California~~M. ~~Pursuant to the Amendment~~D., ~~the~~Ph.D. ~~Company agreed~~ to ~~lease~~serve ~~from~~on the ~~Utah~~Board, ~~Avenue~~effective ~~Landlord~~immediately, ~~two~~and ~~additional~~until ~~suites~~Dr. inBreitmeyer’s ansuccessor ~~additional~~is ~~building~~elected onand ~~Utah Avenue with a total of approximately 3~~qualified,~~531~~ ~~rentable~~or ~~square~~sooner ~~feet~~in ~~of space (~~the ~~“Additional~~event ~~Leased Space”), effective as~~ of ~~May~~his 14death, ~~2026~~resignation, ~~(the~~or ~~“Expansion Commencement Date”)~~removal. The ~~term~~Board ofhas ~~the~~determined ~~lease~~that ofDr. ~~the~~Breitmeyer ~~Additional~~meets ~~Leased Space is 36 months from~~ the ~~Expansion~~independence ~~Commencement~~standards ~~Date,~~adopted ~~unless~~by ~~earlier terminated pursuant to~~ the ~~terms of the Amendment and the Utah Avenue Lease~~Board.

AsJames ~~previously~~B. ~~disclosed~~Breitmeyer, inM.D., ~~December~~Ph.D. ~~2025,~~currently serves as the ~~Company~~Chief ~~entered~~Executive ~~into~~Officer and director of Altay Therapeutics, Inc. and as Operating Partner of SOLVE FSHD, a ~~termination~~venture ~~agreement~~philanthropy ~~(the~~group, ~~“Termination~~since ~~Agreement”)~~February ~~with~~2026 ~~another~~and ~~landlord~~September ~~(the~~2025, ~~“Harbor~~respectively. ~~Way~~Previously, ~~Landlord”)~~Dr. inBreitmeyer ~~connection~~served as President and Chief Executive Officer of Oncternal Therapeutics, Inc. from February 2016 to June 2025. Dr. Breitmeyer is a veteran biotech executive with experience successfully starting and growing biotechnology organizations. He has been responsible for the ~~termination~~development and implementation of ~~that~~operational ~~certain~~and ~~lease~~drug ~~agreement~~development ~~(the~~strategies, ~~“Harbor~~as ~~Way~~well ~~Lease”)~~as supervising and managing both large organizations and emerging biotechnology companies. Dr. Breitmeyer served as President of Bavarian Nordic, Inc. and Executive Vice President of Bavarian Nordic A/S, a multinational corporation headquartered in Denmark, from February 2013 to July 2015 where he oversaw business operations and development strategy both for ~~certain~~Bavarian ~~premises~~Nordic, ~~located~~Inc. atand ~~170~~Bavarian ~~Harbor~~Nordic ~~Way~~A/S. He served as a director of Zogenix, ~~South~~Inc., ~~San~~then ~~Francisco~~a public pharmaceutical company, ~~California~~from ~~94080~~March ~~that~~2014 until it was acquired by UCB S.A. in March 2022 and was acting Chief Medical Officer of Zogenix from August 2012 to February 2013 where he was responsible for clinical development and regulatory strategy. He previously served as the ~~Company’s~~Executive ~~headquarters~~Vice President of Development and Chief Medical Officer of Cadence Pharmaceuticals Inc., ~~The~~a ~~Harbor~~public ~~Way~~pharmaceutical ~~Lease~~company, ~~consists~~from August 2006 to August 2012, and the Chief Medical Officer of ~~approximately~~Applied 24Molecular Evolution Inc.,~~606~~ ~~square~~a ~~feet~~wholly owned subsidiary of ~~rentable~~Eli ~~space~~Lilly and Co., ~~Pursuant~~a global pharmaceutical company, from December 2001 to ~~the~~August ~~Termination~~2006. ~~Agreement,~~Dr. Breitmeyer was also the ~~Company~~founder, President and Chief Executive Officer of the ~~Harbor~~Harvard ~~Way~~Clinical ~~Landlord~~Research ~~agreed~~Institute, and Chief Medical Officer and Head of Research & Development for North America at Serono Laboratories Inc., an international biopharmaceutical company. Dr. Breitmeyer served as a founding collaborator and scientific advisor to ~~terminate~~Immunogen Inc., a biotechnology company, and held clinical and teaching positions at the ~~Harbor~~Dana ~~Way~~Farber ~~Lease~~Cancer ~~effective~~Institute and Harvard Medical School. Dr. Breitmeyer previously served as a director of ~~May~~Otonomy, 15Inc. Dr. Breitmeyer earned his B.A. in Chemistry from the University of California, ~~2026~~Santa Cruz and his M.D. and Ph.D. from Washington University School of Medicine and is Board Certified in Internal Medicine and Oncology. He holds an active California medical license. The Board believes that Dr. Breitmeyer’s perspective and experience as Altay’s CEO and director, as well as his depth of operating and senior management experience in the pharmaceutical industry in both private and public organizations and educational background, provide him with the qualifications and abilities to serve as a director.

Dr. Breitmeyer will be entitled to receive cash and equity compensation for his service on the Board and committees thereof in the standard amounts previously approved by the Board and as set forth in the Vaxart, Inc. Non-Employee Director Compensation Program.

Dr. Breitmeyer also entered into the Company’s standard form of indemnification agreement, the form of which is filed as Exhibit 10.3 to the Company’s Current Report on Form 8-K (File No. 001-35285), filed with the U.S. Securities and Exchange Commission on February 20, 2018.

There are no arrangements or understandings between Dr. Breitmeyer and any other persons, pursuant to which he was appointed as a member of the Board. There are no family relationships between Dr. Breitmeyer and any of the Company’s directors or executive officers. Dr. Breitmeyer is not a party to any current or proposed transaction with the Company for which disclosure is required under Item 404(a) of Regulation S-K.

Item 7.01

Regulation FD Disclosure.

On April 23, 2026, the Company issued a press release announcing the appointment of Dr. Breitmeyer as a member of the Board. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 7.01, and Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, regardless of any general incorporation language in such filing.

Item 9.01

Financial Statements and Exhibits.

Exhibit No.		Description
99.1		Press Release, dated April 23, 2026.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, ~~as amended,~~ the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: April 21, 2026	VAXART, INC.
Date: April 23, 2026		VAXART, INC.
	By:	/s/ Steven Lo
		/s/ Steven Lo
		Steven Lo
		President and Chief Executive Officer

Filing Compare · Vaxart, Inc.